Cathrine Broberg Vågbø
Cathrine Broberg Vågbø
PhD, Senior Engineer, Proteomics and Modomics Experimental Core Facility (PROMEC)
Department of Clinical and Molecular Medicine Faculty of Medicine and Health SciencesBackground and activities
Cathrine Broberg Vågbø has a PhD in molecular medicine and is affiliated at the Proteomics and Modomics Experimental Core facility (PROMEC), Department of Clinical and Molecular Medicine, NTNU. Specialized in RNA epitranscriptomics and DNA epigenetics that regulate gene expression and thus almost all aspects of cell biology. The primary research focus is to understand how errors that occur in these systems lead to the development of human disease. Mass spectrometry-based methods are central for the characterization of the regulatory RNA and DNA modifications, methods that are currently part of the analytical repertoire of the PROMEC core facility and used by a number of research groups nationally and internationally.
Publications
Published 37 articles (PubMed) in peer-reviewed international journals. Currently > 4000 citations and an h-index of 23 (ResearcherID).
Statistics: Journal (impact factor, number of publications): Nature (43.1, 2), Cell (38.6, 1), Nat Neurosci (21.1, 1), Mol Cell (14.5, 2), Sci Adv (13.1, 1), Genes&Dev (12.6, 2), Nat Commun (11.9, 2), EMBO J (11.2, 2), Nucleic Acids Res (11.1, 6), J Cell Biol (9.6, 1), Am J Hum Genet (9.0, 1), Cell Rep (8.7, 2), Oncotarget (6.0, 1), J Transl Med (5.5, 1), Epigenet Chromatin (5.2, 1), DNA Rep (4.9, 5), J Biol Chem (4.6, 1), Cell Discov (4.5, 1), Sci Rep (4.5, 1), Mol Cell Biol (4.4, 1), PlosOne (3.5, 1), J Pharmacol Exp Ther (3.0, 1), F1000Res (1.7, 1), J Clin Pharm (1.7, 1).
Authored textbook chapter: Genomic Uracil: Evolution, Biology, Immunology and Disease, ISBN 9813233494, World Scientific publishing (2018).
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
2021
- (2021) Insight into ALKBH8-related intellectual developmental disability based on the first pathogenic missense variant. Human Genetics.
- (2021) Splice site m<sup>6</sup>A methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell. vol. 184 (12).
- (2021) ALKBH3 partner ASCC3 mediates P-body formation and selective clearance of MMS-induced 1-methyladenosine and 3-methylcytosine from mRNA. Journal of Translational Medicine. vol. 19 (1).
2020
- (2020) Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication. Science Advances. vol. 6 (22).
- (2020) Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma. Nucleic Acids Research (NAR). vol. 48 (8).
- (2020) The Mammalian Cap-Specific m<sup>6</sup>Am RNA Methyltransferase PCIF1 Regulates Transcript Levels in Mouse Tissues. Cell reports. vol. 32 (7).
- (2020) RNA in DNA repair. DNA Repair. vol. 95.
2019
- (2019) The DNA modification N6-methyl-2 '-eoxyadenosine (m6dA) drives activity-induced gene expression and is required for fear extinction. Nature Neuroscience. vol. 22 (4).
- (2019) Recessive Truncating Mutations in ALKBH8 Cause Intellectual Disability and Severe Impairment of Wobble Uridine Modification. American Journal of Human Genetics. vol. 104 (6).
- (2019) The human methyltransferase ZCCHC4 catalyses N6-methyladenosine modification of 28S ribosomal RNA. Nucleic Acids Research (NAR). vol. 48 (2).
- (2019) 5-hydroxymethylcytosine marks mammalian origins acting as a barrier to replication. Scientific Reports. vol. 9.
2017
- (2017) A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA dealkylation repair. Nature. vol. 551 (7680).
- (2017) m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes & Development. vol. 31 (10).
- (2017) Genome-wide profiling of DNA 5-hydroxymethylcytosine during rat Sertoli cell maturation. Cell Discovery. vol. 3.
- (2017) Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. OncoTarget. vol. 8 (12).
2016
- (2016) DNA base modifications in honey bee and fruit fly genomes suggest an active demethylation machinery with species- and tissue-specific turnover rates. Biochemistry and Biophysics Reports. vol. 6.
- (2016) Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells. Epigenetics & Chromatin. vol. 9.
- (2016) Biochemical reconstitution of TET1-TDG-BER-dependent active DNA demethylation reveals a highly coordinated mechanism. Nature Communications. vol. 7.